Avaliação de um gel contendo fluoreto e estanho como uma opção de tratamento profissional para o controle da erosão do esmalte e da dentina / Evaluation of a gel containing fluoride and stannous as an option for the professional treatment of enamel and dentin erosion

Este estudo teve o objetivo de desenvolver um gel experimental contendo flúor e estanho, como uma opção de tratamento profissional, para ser utilizado na prevenção da erosão dental. Foram utilizados 50 fragmentos (4mm × 4mm × 2mm) de esmalte e 50 de dentina, obtidos de incisivos bovinos. Os fragmentos foram incluídos em resina acrílica, planificados e polidos. Em seguida, uma fita adesiva foi posicionada sobre a superfície polida desses espécimes, deixando uma janela de 4mm × 1mm exposta aos testes subsequentes. Os espécimes foram previamente erodidos (10min em solução de ácido cítrico a 1%, pH~2,4) e distribuídos aleatoriamente em cinco grupos experimentais (n=10 para cada substrato), de acordo com os seguintes tratamentos: 1. F+Sn+HPMC: Gel de fluoreto de sódio e cloreto de estanho experimental (7500 ppm F- e 15000 ppm Sn2+, pH=4,5); 2. F+HPMC: Gel de fluoreto de sódio experimental (7500 ppm F-, pH=4,5); 3. Comercial: Gel de flúor fosfato acidulado comercial - APF (12300 ppm F-, pH=3,2); 4. Placebo: Gel placebo (Hidroxipropil MetilceluloseHPMC, sem componentes ativos); 5. Controle negativo: sem tratamento; aplicados por 60 s. Na sequência, os espécimes foram submetidos a uma ciclagem de erosão-re-deposição mineral, que consistia em 5 min de imersão em solução de ácido cítrico a 0,3% (pH~2,6), seguido de imersão em saliva artificial por 60min, 4x/dia, durante 5 dias. A perda de superfície dos espécimes (PS em m) foi determinada com um perfilômetro óptico após 5, 10 e 20 dias de ciclagem. Os dados obtidos foram analisados com ANOVA de dois fatores de medidas repetidas, considerando um nível de significância de 5%. Para o esmalte, o placebo não diferiu do controle em nenhum tempo experimental, e ambos apresentaram significativamente a maior PS. Após 5 e 10 dias: (F+Sn+HPMC)=(comercial)<(F+HPMC)<(placebo)=(controle). Após 20 dias: (F+Sn+HPMC)=(F+HPMC)=(comercial)<(controle)=(placebo). Para dentina, no 5º dia: (comercial)=(F+Sn+HPMC)=(F+HPMC)<(controle)=(placebo). No 10º dia, os grupos F+Sn+HMC, comercial e F+HPMC continuaram apresentando menor PS do que o controle e o placebo, porém, F+HPMC não diferiu significativamente desses dois últimos grupos. No 20º dia, somente o comercial apresentou menor PS que controle e placebo. Considerando as limitações desse estudo in vitro, pode-se concluir que o gel de F+Sn+HPMC foi capaz de controlar a progressão da erosão dental de maneira semelhante ao gel comercial, que possui 4800 ppm a mais de fluoreto em sua composição, exceto após 20 dias de desafio erosivo na dentina. Esse gel é uma alternativa clínica viável, podendo ser potencialmente utilizado em conjunto com produtos de uso diário, visando o aumento da proteção contra erosão em indivíduos com alto risco para erosão dental.

Fratura idiopática de mandíbula atrófica / Idiopathic fracture of atrophic jaw / Fractura idiopática de mandíbula atrófica

Objetivo: Discorrer sobre o tratamento cirúrgico de uma fratura idiopática de mandíbula atrófica. Relato de caso: Idosa compareceu à emergência de um hospital referência em traumas na Paraíba relatando dificuldade ao se alimentar, impossibilidade de uso da prótese dentaria, sintomatologia dolorosa em região mandibular direita com processo infeccioso ativo, sem histórico de trauma direto em face. Ao exame tomográfico constatou-se fratura em mandíbula atrófica com presença de dente incluso na região. Diante do quadro, optou-se por iniciar antibioticoterapia empírica e planejou-se tratamento cirúrgico de reconstrução mandibular com sistema load-sharing, tendo auxílio de biomodelo para conformação prévia da placa. Conclusão: O correto planejamento e escolha do sistema de fixação são fundamentais para o sucesso do tratamento. O uso de biomodelo com pré modelagem de placa mostrou-se positivo por otimizar o tempo cirúrgico, reduzindo os riscos inerentes ao procedimento nesta faixa etária e a utilização de sistema capaz de suportar a carga sofrida na estrutura óssea comprometida nestes casos é mandatório... (AU)

Objective: to discuss the surgical treatment of an idiopathic fracture of the atrophic mandible. Case report: elderly woman attended the emergency department of the Emergency and Trauma Hospital Dom Luiz Gonzaga Fernandes, in Campina Grande, Brazil. The patient reported pain on eating and inability to use her denture as painful symptoms in the right mandibular region with active fistula, without any records of facial trauma. Tomographic examination revealed an atrophic mandibular fracture with an impacted tooth in the region. The following procedures were performed: antibiotic therapy, surgical fixation using a 2.4mm pre-molded plate, shaped using a biomodel, and fistulectomy. Conclusion: Thus, to plan accordingly aiming to minimize the surgical time and its associate damage and the use of appropriate fixation systems capable of supporting the load on the compromised bone are essential to a successful treatment, specially with elderly patients due their general health condition and preexistent comorbities... (AU)

Objetivo: Discutir sobre el tratamiento quirúrgico de una fractura idiopática de la mandíbula atrófica. Caso clínico: Anciana compareció al servicio de urgencias del Hospital de Emergencia y Trauma de Campina Grande Dom Luiz Gonzaga Fernandes, PB, relatando dificultad para alimentarse, imposibilidad de uso de prótesis dental, sintomatología dolorosa en la región mandibular derecha con fístula activa, sin antecedentes de traumatismo directo en la cara. El examen tomográfico presentó una fractura mandibular atrófica con presencia de un diente incluido en la región. Como resultado se realizó antibioticoterapia, procedimiento de fijación quirúrgica con una placa de 2,4 mm premoldeada en biomodelo y fistulectomía. Conclusión: De esta forma, el correcto planeamiento para minimizar el tiempo quirúrgico y los daños asociados, principalmente en los ancianos por su estado general de salud y comorbilidades preexistentes, la utilización de sistemas de fijación adecuados capaces de soportar la carga sufrida en los huesos comprometidos, es fundamental para el éxito del tratamiento... (AU)

Cytotoxicity of human antibodies targeting the circumsporozoite protein is amplified by 3D substrate and correlates with protection.

Human monoclonal antibodies (hmAbs) targeting the Plasmodium falciparum circumsporozoite protein (PfCSP) on the sporozoite surface are a promising tool for preventing malaria infection. However, their mechanisms of protection remain unclear. Here, using 13 distinctive PfCSP hmAbs, we provide a comprehensive view of how PfCSP hmAbs neutralize sporozoites in host tissues. Sporozoites are most vulnerable to hmAb-mediated neutralization in the skin. However, rare but potent hmAbs additionally neutralize sporozoites in the blood and liver. Efficient protection in tissues mainly associates with high-affinity and high-cytotoxicity hmAbs inducing rapid parasite loss-of-fitness in the absence of complement and host cells in vitro. A 3D-substrate assay greatly enhances hmAb cytotoxicity and mimics the skin-dependent protection, indicating that the physical stress imposed on motile sporozoites by the skin is crucial for unfolding the protective potential of hmAbs. This functional 3D cytotoxicity assay can thus be useful for downselecting potent anti-PfCSP hmAbs and vaccines.

Bioprocess optimization for lactic and succinic acid production from a pulp and paper industry side stream.

The effective and cheap production of platform chemicals is a crucial step towards the transition to a bio-based economy. In this work, biotechnological methods using sustainable, cheap, and readily available raw materials bring bio-economy and industrial microbiology together: Microbial production of two platform chemicals is demonstrated [lactic (LA) and succinic acid (SA)] from a non-expensive side stream of pulp and paper industry (fibre sludge) proposing a sustainable way to valorize it towards economically important monomers for bioplastics formation. This work showed a promising new route for their microbial production which can pave the way for new market expectations within the circular economy principles. Fibre sludge was enzymatically hydrolysed for 72 h to generate a glucose rich hydrolysate (100 g·L-1 glucose content) to serve as fermentation medium for Bacillus coagulans A 541, A162 strains and Actinobacillus succinogenis B1, as well as Basfia succiniciproducens B2. All microorganisms were investigated in batch fermentations, showing the ability to produce either lactic or succinic acid, respectively. The highest yield and productivities for lactic production were 0.99 g·g-1 and 3.75 g·L-1·h-1 whereas the succinic acid production stabilized at 0.77 g·g-1 and 1.16 g·L-1·h-1.

Cryo-EM structures of anti-malarial antibody L9 with circumsporozoite protein reveal trimeric L9 association and complete 27-residue epitope.

Monoclonal antibody L9 recognizes the Plasmodium falciparum circumsporozoite protein (PfCSP) and is highly protective following controlled human malaria challenge. To gain insight into its function, we determined cryoelectron microscopy (cryo-EM) structures of L9 in complex with full-length PfCSP and assessed how this recognition influenced protection by wild-type and mutant L9s. Cryo-EM reconstructions at 3.6- and 3.7-Å resolution revealed L9 to recognize PfCSP as an atypical trimer. Each of the three L9s in the trimer directly recognized an Asn-Pro-Asn-Val (NPNV) tetrapeptide on PfCSP and interacted homotypically to facilitate L9-trimer assembly. We analyzed peptides containing different repeat tetrapeptides for binding to wild-type and mutant L9s to delineate epitope and homotypic components of L9 recognition; we found both components necessary for potent malaria protection. Last, we found the 27-residue stretch recognized by L9 to be highly conserved in P. falciparum isolates, suggesting the newly revealed complete L9 epitope to be an attractive vaccine target.

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.

BACKGROUND: New approaches for the prevention and elimination of malaria, a leading cause of illness and death among infants and young children globally, are needed. METHODS: We conducted a phase 1 clinical trial to assess the safety and pharmacokinetics of L9LS, a next-generation antimalarial monoclonal antibody, and its protective efficacy against controlled human malaria infection in healthy adults who had never had malaria or received a vaccine for malaria. The participants received L9LS either intravenously or subcutaneously at a dose of 1 mg, 5 mg, or 20 mg per kilogram of body weight. Within 2 to 6 weeks after the administration of L9LS, both the participants who received L9LS and the control participants underwent controlled human malaria infection in which they were exposed to mosquitoes carrying Plasmodium falciparum (3D7 strain). RESULTS: No safety concerns were identified. L9LS had an estimated half-life of 56 days, and it had dose linearity, with the highest mean (±SD) maximum serum concentration (Cmax) of 914.2±146.5 µg per milliliter observed in participants who had received 20 mg per kilogram intravenously and the lowest mean Cmax of 41.5±4.7 µg per milliliter observed in those who had received 1 mg per kilogram intravenously; the mean Cmax was 164.8±31.1 in the participants who had received 5 mg per kilogram intravenously and 68.9±22.3 in those who had received 5 mg per kilogram subcutaneously. A total of 17 L9LS recipients and 6 control participants underwent controlled human malaria infection. Of the 17 participants who received a single dose of L9LS, 15 (88%) were protected after controlled human malaria infection. Parasitemia did not develop in any of the participants who received 5 or 20 mg per kilogram of intravenous L9LS. Parasitemia developed in 1 of 5 participants who received 1 mg per kilogram intravenously, 1 of 5 participants who received 5 mg per kilogram subcutaneously, and all 6 control participants through 21 days after the controlled human malaria infection. Protection conferred by L9LS was seen at serum concentrations as low as 9.2 µg per milliliter. CONCLUSIONS: In this small trial, L9LS administered intravenously or subcutaneously protected recipients against malaria after controlled infection, without evident safety concerns. (Funded by the National Institute of Allergy and Infectious Diseases; VRC 614 ClinicalTrials.gov number, NCT05019729.).

Development of a sodium fluoride and stannous chloride-containing gel for treatment of dental erosion.

This study synthesized and tested experimental gels containing fluoride (F-) and stannous (Sn2+) ions for the control of dental erosion. Enamel and dentin polished specimens were eroded (1% citric acid solution, 10 min) and randomly allocated into 5 groups (n=10): Placebo - Hydroxypropyl Methylcellulose (HMC) gel; F+Sn+HMC - 7,500 ppm F- / 15,000 ppm Sn2+; F+HMC - 7,500 ppm F-; Commercial acidulated phosphate fluoride gel (12,300 ppm F-); and Control - no treatment. After treatment (applied for 60 s), specimens underwent an erosion-remineralization cycling (5 min in 0.3% citric acid solution, 60 min in artificial saliva, 4×/day, 20 days). Surface loss (SL, in µm) was determined after the 5th, 10th and 20th days of cycling (α=0.05). For enamel, after 5 and 10 days, F+Sn+HMC presented the lowest SL, which did not differ from the commercial gel. After 20 days, no differences were found between commercial, F+HMC, and F+Sn+HMC groups. Placebo did not differ from the control at any time points, and both groups presented the highest SL when compared to the other groups. For dentin, on the 5th day, F+Sn+HMC, F+HMC and commercial did not differ significantly, showing lower SL than the control and the placebo. On the 10th day, F+Sn+HMC and commercial presented the lowest SL compared to control and placebo. After 20 days, only the commercial gel showed lower SL than the control and placebo. Thus, the experimental F+Sn+HMC gel was able to control the progression of tooth erosion.

Este estudo desenvolveu e testou géis experimentais contendo íons fluoreto (F-) e estanho (Sn2+) para o controle da erosão dentária. Os espécimes polidos, de esmalte e dentina, foram previamente erodidos (solução de ácido cítrico a 1%, 10 min) e alocados aleatoriamente em 5 grupos (n = 10): Placebo - gel de hidroxipropilmetilcelulose (HMC); F + Sn + HMC - 7.500 ppm F- / 15.000 ppm Sn2+; F + HMC - 7.500 ppm F-; Gel de flúor fosfato acidulado comercial (12.300 ppm F-); e Controle - sem tratamento. Após o tratamento (aplicado por 60 s), os espécimes foram submetidos a uma ciclagem de erosão-remineralização (5 min em solução de ácido cítrico a 0,3%, 60 min em saliva artificial, 4 × / dia, 20 dias). A perda de superfície (SL, em µm) foi determinada após o 5º, 10º e 20º dias de ciclagem (α = 0,05). Para o esmalte, após 5 e 10 dias, o F + Sn + HMC apresentou a menor PS, não diferindo do gel comercial. Após 20 dias, não foram encontradas diferenças entre os grupos comercial, F + HMC e F + Sn + HMC. O placebo não diferiu do controle em nenhum momento, e ambos os grupos apresentaram a maior PS, comparado aos demais grupos. Para dentina, no 5º dia , F + Sn + HMC, F + HMC e comercial não diferiram significativamente, apresentando menor PS que o grupo controle e placebo. No 10º dia, F+Sn+HMC e comercial apresentaram a menor PS comparado ao grupo controle e placebo. No 20º dia, apenas o gel comercial apresentou PS menor que o controle e o placebo. Assim, o gel experimental F + Sn + HMC foi capaz de controlar a progressão da erosão dentária.

Development of a sodium fluoride and stannous chloride-containing gel for treatment of dental erosion

Resumo Este estudo desenvolveu e testou géis experimentais contendo íons fluoreto (F-) e estanho (Sn2+) para o controle da erosão dentária. Os espécimes polidos, de esmalte e dentina, foram previamente erodidos (solução de ácido cítrico a 1%, 10 min) e alocados aleatoriamente em 5 grupos (n = 10): Placebo - gel de hidroxipropilmetilcelulose (HMC); F + Sn + HMC - 7.500 ppm F- / 15.000 ppm Sn2+; F + HMC - 7.500 ppm F-; Gel de flúor fosfato acidulado comercial (12.300 ppm F-); e Controle - sem tratamento. Após o tratamento (aplicado por 60 s), os espécimes foram submetidos a uma ciclagem de erosão-remineralização (5 min em solução de ácido cítrico a 0,3%, 60 min em saliva artificial, 4 × / dia, 20 dias). A perda de superfície (SL, em µm) foi determinada após o 5º, 10º e 20º dias de ciclagem (α = 0,05). Para o esmalte, após 5 e 10 dias, o F + Sn + HMC apresentou a menor PS, não diferindo do gel comercial. Após 20 dias, não foram encontradas diferenças entre os grupos comercial, F + HMC e F + Sn + HMC. O placebo não diferiu do controle em nenhum momento, e ambos os grupos apresentaram a maior PS, comparado aos demais grupos. Para dentina, no 5º dia , F + Sn + HMC, F + HMC e comercial não diferiram significativamente, apresentando menor PS que o grupo controle e placebo. No 10º dia, F+Sn+HMC e comercial apresentaram a menor PS comparado ao grupo controle e placebo. No 20º dia, apenas o gel comercial apresentou PS menor que o controle e o placebo. Assim, o gel experimental F + Sn + HMC foi capaz de controlar a progressão da erosão dentária.

Abstract: This study synthesized and tested experimental gels containing fluoride (F-) and stannous (Sn2+) ions for the control of dental erosion. Enamel and dentin polished specimens were eroded (1% citric acid solution, 10 min) and randomly allocated into 5 groups (n=10): Placebo - Hydroxypropyl Methylcellulose (HMC) gel; F+Sn+HMC - 7,500 ppm F- / 15,000 ppm Sn2+; F+HMC - 7,500 ppm F-; Commercial acidulated phosphate fluoride gel (12,300 ppm F-); and Control - no treatment. After treatment (applied for 60 s), specimens underwent an erosion-remineralization cycling (5 min in 0.3% citric acid solution, 60 min in artificial saliva, 4×/day, 20 days). Surface loss (SL, in µm) was determined after the 5th, 10th and 20th days of cycling (α=0.05). For enamel, after 5 and 10 days, F+Sn+HMC presented the lowest SL, which did not differ from the commercial gel. After 20 days, no differences were found between commercial, F+HMC, and F+Sn+HMC groups. Placebo did not differ from the control at any time points, and both groups presented the highest SL when compared to the other groups. For dentin, on the 5th day, F+Sn+HMC, F+HMC and commercial did not differ significantly, showing lower SL than the control and the placebo. On the 10th day, F+Sn+HMC and commercial presented the lowest SL compared to control and placebo. After 20 days, only the commercial gel showed lower SL than the control and placebo. Thus, the experimental F+Sn+HMC gel was able to control the progression of tooth erosion.

Effects of moderate alcohol consumption on behavior and neural systems of Wistar rats.

Chronic alcohol consumption affects various neurotransmitters, especially those implicated in the transitioning to alcohol use disorders (particularly dopaminergic and CRFergic systems). Few studies have investigated moderate alcohol consumption and its harmful consequences. The objective of this work was to analyze behavioral and neurochemical (dopaminergic and CRFergic systems) alterations during chronic moderate alcohol consumption. Twelve male Wistar rats were submitted to an intermittent alcohol ingestion protocol (alcohol group) for four weeks. The control group consisted of six rats. Open Field and Elevated Plus Maze tests were used for analysis of motor and anxiety-like behaviors. Immunohistochemistry analysis was performed in dopaminergic and CRFergic systems. Animals exposed to alcohol consumed moderate doses, chronic and intermittently. Behavioral tests detected fewer fecal boli in the alcohol exposed group, and immunohistochemical analysis indicated fewer dopamine-immunoreactive cells in the ventral tegmental area, and more CRF-immunoreactive cells in the anterior cingulate cortex and dorsolateral septum in this group. Thus we concluded that Wistar rats that consumed moderate doses of alcohol voluntarily and chronically showed a discreet anxiolytic effect in behavior, and a hypodopaminergic and hyperCRFergic neurochemical condition, which together are strong inducers of alcohol consumption predisposing to the development of alcohol use disorder (AUD).

Highly protective antimalarial antibodies via precision library generation and yeast display screening.

The monoclonal antibody CIS43 targets the Plasmodium falciparum circumsporozoite protein (PfCSP) and prevents malaria infection in humans for up to 9 mo following a single intravenous administration. To enhance the potency and clinical utility of CIS43, we used iterative site-saturation mutagenesis and DNA shuffling to screen precise gene-variant yeast display libraries for improved PfCSP antigen recognition. We identified several mutations that improved recognition, predominately in framework regions, and combined these to produce a panel of antibody variants. The most improved antibody, CIS43_Var10, had three mutations and showed approximately sixfold enhanced protective potency in vivo compared to CIS43. Co-crystal and cryo-electron microscopy structures of CIS43_Var10 with the peptide epitope or with PfCSP, respectively, revealed functional roles for each of these mutations. The unbiased site-directed mutagenesis and screening pipeline described here represent a powerful approach to enhance protective potency and to enable broader clinical use of antimalarial antibodies.

Avaliação de um gel contendo fluoreto e estanho como uma opção de tratamento profissional para o controle da erosão do esmalte e da dentina / Evaluation of a gel containing fluoride and stannous as an option for the professional treatment of enamel and dentin erosion

Este estudo teve o objetivo de desenvolver um gel experimental contendo flúor e estanho, como uma opção de tratamento profissional, para ser utilizado na prevenção da erosão dental. Foram utilizados 50 fragmentos (4mm × 4mm × 2mm) de esmalte e 50 de dentina, obtidos de incisivos bovinos. Os fragmentos foram incluídos em resina acrílica, planificados e polidos. Em seguida, uma fita adesiva foi posicionada sobre a superfície polida desses espécimes, deixando uma janela de 4mm × 1mm exposta aos testes subsequentes. Os espécimes foram previamente erodidos (10min em solução de ácido cítrico a 1%, pH~2,4) e distribuídos aleatoriamente em cinco grupos experimentais (n=10 para cada substrato), de acordo com os seguintes tratamentos: 1. F+Sn+HPMC: Gel de fluoreto de sódio e cloreto de estanho experimental (7500 ppm F- e 15000 ppm Sn2+, pH=4,5); 2. F+HPMC: Gel de fluoreto de sódio experimental (7500 ppm F-, pH=4,5); 3. Comercial: Gel de flúor fosfato acidulado comercial - APF (12300 ppm F-, pH=3,2); 4. Placebo: Gel placebo (Hidroxipropil MetilceluloseHPMC, sem componentes ativos); 5. Controle negativo: sem tratamento; aplicados por 60 s. Na sequência, os espécimes foram submetidos a uma ciclagem de erosão-re-deposição mineral, que consistia em 5 min de imersão em solução de ácido cítrico a 0,3% (pH~2,6), seguido de imersão em saliva artificial por 60min, 4x/dia, durante 5 dias. A perda de superfície dos espécimes (PS em m) foi determinada com um perfilômetro óptico após 5, 10 e 20 dias de ciclagem. Os dados obtidos foram analisados com ANOVA de dois fatores de medidas repetidas, considerando um nível de significância de 5%. Para o esmalte, o placebo não diferiu do controle em nenhum tempo experimental, e ambos apresentaram significativamente a maior PS. Após 5 e 10 dias: (F+Sn+HPMC)=(comercial)<(F+HPMC)<(placebo)=(controle). Após 20 dias: (F+Sn+HPMC)=(F+HPMC)=(comercial)<(controle)=(placebo). Para dentina, no 5º dia: (comercial)=(F+Sn+HPMC)=(F+HPMC)<(controle)=(placebo). No 10º dia, os grupos F+Sn+HMC, comercial e F+HPMC continuaram apresentando menor PS do que o controle e o placebo, porém, F+HPMC não diferiu significativamente desses dois últimos grupos. No 20º dia, somente o comercial apresentou menor PS que controle e placebo. Considerando as limitações desse estudo in vitro, pode-se concluir que o gel de F+Sn+HPMC foi capaz de controlar a progressão da erosão dental de maneira semelhante ao gel comercial, que possui 4800 ppm a mais de fluoreto em sua composição, exceto após 20 dias de desafio erosivo na dentina. Esse gel é uma alternativa clínica viável, podendo ser potencialmente utilizado em conjunto com produtos de uso diário, visando o aumento da proteção contra erosão em indivíduos com alto risco para erosão dental.

The light chain of the L9 antibody is critical for binding circumsporozoite protein minor repeats and preventing malaria.

L9 is a potent human monoclonal antibody (mAb) that preferentially binds two adjacent NVDP minor repeats and cross-reacts with NANP major repeats of the Plasmodium falciparum circumsporozoite protein (PfCSP) on malaria-infective sporozoites. Understanding this mAb's ontogeny and mechanisms of binding PfCSP will facilitate vaccine development. Here, we isolate mAbs clonally related to L9 and show that this B cell lineage has baseline NVDP affinity and evolves to acquire NANP reactivity. Pairing the L9 kappa light chain (L9κ) with clonally related heavy chains results in chimeric mAbs that cross-link two NVDPs, cross-react with NANP, and more potently neutralize sporozoites in vivo compared with their original light chain. Structural analyses reveal that the chimeric mAbs bound minor repeats in a type-1 ß-turn seen in other repeat-specific antibodies. These data highlight the importance of L9κ in binding NVDP on PfCSP to neutralize sporozoites and suggest that PfCSP-based immunogens might be improved by presenting ≥2 NVDPs.

Historicizando a trajetória de um pioneiro: Reinier Johannes Antonius Rozestraten (1924-2008) / Historicizing a pioneer: Reinier Johannes Antonius Rozestraten (1924-2008)

As biografias têm ganhado espaço na História das Ciências, no geral e, em específico, na História da Psicologia. Elas têm permitido compreender a atuação de personagens relevantes na história da Psicologia, em diversos locais e, entre eles, no Brasil. Esteartigo se constitui como uma biografia de Reinier Johannes Antonius Rozestraten (1924-2008). A partir de fontes textuais (e.g., memoriais, relatórios, etc.) e orais (entrevista com ex-colegas e ex-alunos), apresentamos cidades pelas quais o biografado passou e parte de suas atividades vinculadas ao campo científico-profissional da Psicologia. As fontes foram analisadas a partir de seu conteúdo. Vemos um ator interessado em uma Psicologia científica, capaz de se envolver em questões aplicadas, do que a de uma personagem vinculada a uma teoria, em especial. Ademais, observamos uma atuação que concorreu à criação e desenvolvimento de Sociedades científico-profissionais. Assim, sua trajetória nos permite compreender os caminhos da Psicologia, no geral, e da Psicologia do Trânsito, em específico, no Brasil.

Biographies have calling attention in the History of Sciences, in general and, in particular, in the History of Psychology. They have allowed us to understand the role of relevant characters in the history Psychology, in different places and, among them, in Brazil. This article is a biography of Reinier Johannes Antonius Rozestraten (1924-2008). From textual (e.g., memorial, research reports, etc.) and oral sources (interview with colleagues and former students), we present cities through which he passed and part of his activities linked to the scientific-professional field of Psychology. Primary sources were analyzed from its contents. We note Rozestraten more interested in scientific psychology, capable of getting involved in applied issues, than that of acharacter linked to a theory, in particular. In addition, we observed an activity that contributed to the creation and development of various scientific-professional societies. Thus, its trajectory allows us to understand the paths of Psychology, in general, and of Traffic Psychology, in specific, in Brazil.

Historicizando a trajetória de um pioneiro: Reinier Johannes Antonius Rozestraten (1924-2008) / Historicizing a pioneer: Reinier Johannes Antonius Rozestraten (1924-2008)

As biografias têm ganhado espaço na História das Ciências, no geral e, em específico, na História da Psicologia. Elas têm permitido compreender a atuação de personagens relevantes na história da Psicologia, em diversos locais e, entre eles, no Brasil. Esteartigo se constitui como uma biografia de Reinier Johannes Antonius Rozestraten (1924-2008). A partir de fontes textuais (e.g., memoriais, relatórios, etc.) e orais (entrevista com ex-colegas e ex-alunos), apresentamos cidades pelas quais o biografado passou e parte de suas atividades vinculadas ao campo científico-profissional da Psicologia. As fontes foram analisadas a partir de seu conteúdo. Vemos um ator interessado em uma Psicologia científica, capaz de se envolver em questões aplicadas, do que a de uma personagem vinculada a uma teoria, em especial. Ademais, observamos uma atuação que concorreu à criação e desenvolvimento de Sociedades científico-profissionais. Assim, sua trajetória nos permite compreender os caminhos da Psicologia, no geral, e da Psicologia do Trânsito, em específico, no Brasil.

Biographies have calling attention in the History of Sciences, in general and, in particular, in the History of Psychology. They have allowed us to understand the role of relevant characters in the history Psychology, in different places and, among them, in Brazil. This article is a biography of Reinier Johannes Antonius Rozestraten (1924-2008). From textual (e.g., memorial, research reports, etc.) and oral sources (interview with colleagues and former students), we present cities through which he passed and part of his activities linked to the scientific-professional field of Psychology. Primary sources were analyzed from its contents. We note Rozestraten more interested in scientific psychology, capable of getting involved in applied issues, than that of acharacter linked to a theory, in particular. In addition, we observed an activity that contributed to the creation and development of various scientific-professional societies. Thus, its trajectory allows us to understand the paths of Psychology, in general, and of Traffic Psychology, in specific, in Brazil.

Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein.

Combinations of monoclonal antibodies (mAbs) against different epitopes on the same antigen synergistically neutralize many viruses. However, there are limited studies assessing whether combining human mAbs against distinct regions of the Plasmodium falciparum (Pf) circumsporozoite protein (CSP) enhances in vivo protection against malaria compared to each mAb alone or whether passive transfer of PfCSP mAbs would improve protection following vaccination against PfCSP. Here, we isolated a panel of human mAbs against the subdominant C-terminal domain of PfCSP (C-CSP) from a volunteer immunized with radiation-attenuated Pf sporozoites. These C-CSP-specific mAbs had limited binding to sporozoites in vitro that was increased by combination with neutralizing human "repeat" mAbs against the NPDP/NVDP/NANP tetrapeptides in the central repeat region of PfCSP. Nevertheless, passive transfer of repeat- and C-CSP-specific mAb combinations did not provide enhanced protection against in vivo sporozoite challenge compared to repeat mAbs alone. Furthermore, combining potent repeat-specific mAbs (CIS43, L9, and 317) that respectively target the three tetrapeptides (NPDP/NVDP/NANP) did not provide additional protection against in vivo sporozoite challenge. However, administration of either CIS43, L9, or 317 (but not C-CSP-specific mAbs) to mice that had been immunized with R21, a PfCSP-based virus-like particle vaccine that induces polyclonal antibodies against the repeat region and C-CSP, provided enhanced protection against sporozoite challenge when compared to vaccine or mAbs alone. Collectively, this study shows that while combining mAbs against the repeat and C-terminal regions of PfCSP provide no additional protection in vivo, repeat mAbs do provide increased protection when combined with vaccine-induced polyclonal antibodies. These data should inform the implementation of PfCSP human mAbs alone or following vaccination to prevent malaria infection.

The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo.

Rare and potent monoclonal antibodies (mAbs) against the Plasmodium falciparum (Pf) circumsporozoite protein (CSP) on infective sporozoites (SPZ) preferentially bind the PfCSP junctional tetrapeptide NPDP or NVDP minor repeats while cross-reacting with NANP central repeats in vitro. The extent to which each of these epitopes is required for protection in vivo is unknown. Here, we assessed whether junction-, minor repeat- and central repeat-preferring human mAbs (CIS43, L9 and 317 respectively) bound and protected against in vivo challenge with transgenic P. berghei (Pb) SPZ expressing either PfCSP with the junction and minor repeats knocked out (KO), or PbCSP with the junction and minor repeats knocked in (KI). In vivo protection studies showed that the junction and minor repeats are necessary and sufficient for CIS43 and L9 to neutralize KO and KI SPZ, respectively. In contrast, 317 required major repeats for in vivo protection. These data establish that human mAbs can prevent malaria infection by targeting three different protective epitopes (NPDP, NVDP, NANP) in the PfCSP repeat region. This report will inform vaccine development and the use of mAbs to passively prevent malaria.

Assessment of Sorbate and Benzoate Content in Mustard, Ketchup and Tomato Sauce by Sub-Minute Capillary Electrophoresis.

RESEARCH BACKGROUND: Sorbate and benzoate are important preservatives in food products, but these compounds can also have genotoxic effects, causing health risks to consumers. In this regard, this study aims to determine the mass fractions of sorbate and benzoate in Brazilian samples of mustard, ketchup and tomato sauce using an adequately validated sub-minute capillary electrophoresis method. EXPERIMENTAL APPROACH: In this study, sorbate and benzoate were evaluated in sauce samples by capillary electrophoresis using a simple sample preparation procedure. Previously, the method was validated according to Eurachem guidelines, and its greenness was assessed by Eco-Scale. RESULTS AND CONCLUSIONS: The fitness for purpose of the method, as well as its suitability for the analysis of the studied matrices and its agreement with the principles of green chemistry were checked and confirmed. Also, according to our findings, among the 30 commercial samples assessed, six of them presented some mislabeling or non-compliance with European or Brazilian legislation, reinforcing the constant need for quality assessment and surveillance of food products. NOVELTY AND SCIENTIFIC CONTRIBUTION: So far, there have been few studies related to investigating the preservatives such as sorbate and benzoate in mustard, ketchup and tomato sauce, highlighting the significance and contribution of the obtained results to the knowledge in the field.

Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodies.

Repeat antigens, such as the Plasmodium falciparum circumsporozoite protein (PfCSP), use both sequence degeneracy and structural diversity to evade the immune response. A few PfCSP-directed antibodies have been identified that are effective at preventing malaria infection, including CIS43, but how these repeat-targeting antibodies might be improved has been unclear. Here, we engineered a humanized mouse model in which B cells expressed inferred human germline CIS43 (iGL-CIS43) B cell receptors and used both vaccination and bioinformatic analysis to obtain variant CIS43 antibodies with improved protective capacity. One such antibody, iGL-CIS43.D3, was significantly more potent than the current best-in-class PfCSP-directed antibody. We found that vaccination with a junctional epitope peptide was more effective than full-length PfCSP at recruiting iGL-CIS43 B cells to germinal centers. Structure-function analysis revealed multiple somatic hypermutations that combinatorically improved protection. This mouse model can thus be used to understand vaccine immunogens and to develop highly potent anti-malarial antibodies.

Functional human IgA targets a conserved site on malaria sporozoites.

Immunoglobulin (Ig)A antibodies play a critical role in protection against mucosal pathogens. However, the role of serum IgA in immunity to nonmucosal pathogens, such as Plasmodium falciparum, is poorly characterized, despite being the second most abundant isotype in blood after IgG. Here, we investigated the circulating IgA response in humans to P. falciparum sporozoites that are injected into the skin by mosquitoes and migrate to the liver via the bloodstream to initiate malaria infection. We found that circulating IgA was induced in three independent sporozoite-exposed cohorts: individuals living in an endemic region in Mali, malaria-naïve individuals immunized intravenously with three large doses of irradiated sporozoites, and malaria-naïve individuals exposed to a single controlled mosquito bite infection. Mechanistically, we found evidence in an animal model that IgA responses were induced by sporozoites at dermal inoculation sites. From malaria-resistant individuals, we isolated several IgA monoclonal antibodies that reduced liver parasite burden in mice. One antibody, MAD2-6, bound to a conserved epitope in the amino terminus of the P. falciparum circumsporozoite protein, the dominant protein on the sporozoite surface. Crystal structures of this antibody revealed a unique mode of binding whereby two Fabs simultaneously bound either side of the target peptide. This study reveals a role for circulating IgA in malaria and identifies the amino terminus of the circumsporozoite protein as a target of functional antibodies.

Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria.

The most advanced malaria vaccine, RTS,S, includes the central repeat and C-terminal domains of the Plasmodium falciparum circumsporozoite protein (PfCSP). We have recently isolated human antibodies that target the junctional region between the N-terminal and repeat domains that are not included in RTS,S. Due to the fact that these antibodies protect against malaria challenge in mice, their epitopes could be effective vaccine targets. Here, we developed immunogens displaying PfCSP junctional epitopes by genetic fusion to either the N-terminus or B domain loop of the E2 protein from chikungunya (CHIK) alphavirus and produced CHIK virus-like particles (CHIK-VLPs). The structural integrity of these junctional-epitope-CHIK-VLP immunogens was confirmed by negative-stain electron microscopy. Immunization of these CHIK-VLP immunogens reduced parasite liver load by up to 95% in a mouse model of malaria infection and elicited better protection than when displayed on keyhole limpet hemocyanin, a commonly used immunogenic carrier. Protection correlated with PfCSP serum titer. Of note, different junctional sequences elicited qualitatively different reactivities to overlapping PfCSP peptides. Overall, these results show that the junctional epitopes of PfCSP can induce protective responses when displayed on CHIK-VLP immunogens and provide a basis for the development of a next generation malaria vaccine to expand the breadth of anti-PfCSP immunity.